3S Pharmaceutical Group
3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.
3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.
We look forward to having opportunity to discuss potential collaboration with you.
Zhao Peng
Senior BD Manager
AnHeart Therapeutics
Dr. Weiqing Wang
Associate Director of BDDr. Akira Liu
Director of BDAnsun Biopharma
Max Wang
BDBeijing Continent Pharmaceutical Co., Ltd.
A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.
Qin Li
Associate Director,Business DevelopmentBioPegasus, LLC
BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.
BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.
BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.
Dr. Tianlin Ma
FounderBiosion Inc.,
During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.